CRL
Charles River Laboratories International Inc.

909
Loading...
Loading...
News
all
press releases
CRL Stock Rises Following New Strategic Oncology Collaborations
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
Zacks·12h ago
News Placeholder
More News
News Placeholder
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Zacks·8d ago
News Placeholder
Danaher Gains From Business Strength Amid Persisting Headwinds
DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.
Zacks·10d ago
News Placeholder
Charles River Stock May Benefit From Joining EASYGEN Consortium
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Zacks·11d ago
News Placeholder
Interpreting Charles River (CRL) International Revenue Trends
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zacks·1mo ago
News Placeholder
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Zacks·1mo ago
News Placeholder
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago

Latest CRL News

View

Advertisement. Remove ads.

Advertisement. Remove ads.